Cancer Protein Description
This report provides a detailed description of a selected cancer protein with information collected from various sources, including UniProt, the Wellcome Trust Sanger Institute’s Catalogue of Somatic Mutations in Cancer (COSMIC), and the Atlas of Genetics and Cytogenetics in Oncology and Haematology.
| Protein Name: | PUS10 |
| Gene Name: | PUS10 |
| Protein Full Name: | Putative tRNA pseudouridine synthase Pus10 |
| Alias: | CCDC139; Coiled-coil domain-containing protein 139; EC=5.4.99.-; TRNA pseudouridine 55 synthase; TRNA pseudouridylate synthase; TRNA-uridine isomerase |
| Mass (Da): | 60244 |
| Number AA: | 529 |
| UniProt ID: | Q3MIT2 |
| Locus ID: | 150962 |
| COSMIC ID: | PUS10 |
| Gene location on chromosome: | 2p16.1 |
| Cancer protein type: | UNCLEAR |
| Effect of cancer mutation on protein: | UNCLEAR |
| Effect of active protein on cancer: | UNCLEAR |
| Number of cancer specimens: | 19868 |
| Percent of cancer specimens with mutations: | 0.37 |
| Normal role description: | PUS10 is a enzyme required for post-transcriptional conversion of uridine to pseudouridine in structural RNAs. PUS10 can catalyze the pseudouridination of tRNAs, rRNAs and spliceosome RNAs. PUS10 can also act as a RNA chaperone to promote the correct folding of tRNAs. PUS10 may mediate apoptosis caused by TNF-related apoptosis-inducing ligand (TRAIL) signalling. Few mutations of PUS10 have been recorded and their effects have not been functionally characterized. PUS10 dysfunction may mediate cancer development through aberrant apoptosis signalling or post-transcriptional modifications of structural RNAs which has implications in transcription and translation. |
| Commentary on involvement of protein in cancer: | No entry in Atlasgeneticsoncology.org. Less than 3% mutations in kidney. |